✦ LIBER ✦

Clinical decision-making as the basis for assessing agreement between measures of the International Normalized Ratio

✍ Scribed by K. M. SHERMOCK; J. T. CONNOR; D. C. LAVALLEE; M. B. STREIFF

Book ID: 109152783
Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 208 KB
Volume: 7
Category: Article
ISSN: 1538-7933
DOI: 10.1111/j.1538-7836.2008.03225.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCV28 THE CLINICAL IMPACT OF DIFFERENCES

PCV28 THE CLINICAL IMPACT OF DIFFERENCES BETWEEN TWO MEASURES OF THE INTERNATIONAL NORMALIZED RATIO (INR)

✍ KM Shermock; BL Pinto; M Streiff 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB

PCV76 LONGITUDINAL ASSESSMENT OF THE CLI

PCV76 LONGITUDINAL ASSESSMENT OF THE CLINICAL UTILITY OF POINT-OF-CARE MEASUREMENT DEVICES FOR DETERMINING THE INTERNATIONAL NORMALIZED RATIO

✍ KM Shermock; DC Lavallee; J Conner; J Fink; L Bragg 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 69 KB

The International Normalized Ratio as a

The International Normalized Ratio as a measure of anticoagulation: Significance for the management of the dental outpatient

✍ Sean Meehan; Mark C. Schmidt; Paul F. Mitchell 📂 Article 📅 1997 🏛 Special Care Dentistry Association 🌐 English ⚖ 313 KB

PCV153 FAILURE OF THE BLAND-ALTMAN METHO

PCV153 FAILURE OF THE BLAND-ALTMAN METHOD TO IDENTIFY CLINICALLY IMPORTANT DISAGREEMENT BETWEEN MEASURES OF THE INTERNATIONAL NORMALIZED RATIO

✍ KM Shermock 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB

The Disease Activity Score is not suitab

The Disease Activity Score is not suitable as the sole criterion for initiation and evaluation of anti–tumor necrosis factor therapy in the clinic: Discordance between assessment measures and limitations in questionnaire use for regulatory purposes

✍ Frederick Wolfe; Kaleb Michaud; Theodore Pincus; Daniel Furst; Edward Keystone 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 218 KB 👁 2 views

## Abstract ## Objective The Disease Activity Score (DAS) is widely used in clinical trials. A DAS of 5.1 defines the level of severe rheumatoid arthritis (RA) and is the criterion for the initiation of anti–tumor necrosis factor therapy in the UK and The Netherlands. In North America, similar rul

MAGNA CARTAThe Great CharterPreamble

📂 Fiction 🌐 English ⚖ 11 KB 👁 18 views